Search clinical trials for: AZD9833 with everolimus

Total 18231 results

Swiss Group for Clinical Cancer Research

Completed

Sorafenib Tosylate With or Without Everolimus in Treating Patients With Localized, Unresectable, or Metastatic Liver Cancer

Liver Cancer

Switzerland, Austria, Hungary
Medtronic Vascular
Medtronic Bakken Research Center

Completed

Randomized, Two-arm, Non-inferiority Study Comparing Endeavor-Resolute Stent With Abbot Xience-V Stent (RESOLUTE-AC)

Coronary Artery Disease

Switzerland
University College, London

Terminated

Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or Metastatic Head and Neck Cancer (DORA)

Head and Neck Cancer

United Kingdom
Peking University First Hospital

Recruiting

Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy

Renal Cell Carcinoma, Clear Cell, Somatic

China
Memorial Sloan Kettering Cancer Center
New York University; Novartis Pharmaceuticals; University of Hawaii

Completed

RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder

Bladder Cancer

United States
University of Cologne

Completed

SORAVE - Sorafenib and Everolimus in Solid Tumors (SORAVE)

Non-Small Cell Lung Cancer | Unspecified Adult Solid Tumor, Protocol Specific

Germany
Foundation of Cardiovascular Research and Education...

Completed

The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente (TWENTE)

Coronary Artery Disease | Angina Pectoris | Unstable Angina Pectoris | Coronary Stenosis | Coronary Restenosis

Netherlands
Seung-Jung Park
CardioVascular Research Foundation, Korea

Completed

Diffuse Type In-Stent Restenosis After Drug-Eluting Stent (DES-ISR)

In-stent Restenosis

Korea, Republic of
Seung-Jung Park
CardioVascular Research Foundation, Korea

Completed

Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III) (LONG-DES-III)

Coronary Artery Disease

Korea, Republic of
Eisai Inc.
Merck Sharp & Dohme LLC

Active, not recruiting

Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma

Renal Cell Carcinoma

Spain, Canada, Portugal, Korea, Republic of, Taiwan, United States, Netherlands, United Kingdom, Czechia, Italy, Finland, Greece, Romania, Australia, Poland, Russian Federation
University Hospital, Strasbourg, France

Active, not recruiting

Multicenter Randomized Two-arms Study Evaluating the BK Viral Clearance in Kidney Transplant Recipients With BK Viremia. (BK EVER)

BK Virus Nephropathy After Kidney Transplantation

France
National Taiwan University Hospital
Taipei Veterans General Hospital, Taiwan; National Cheng-Kung University Hospital

Completed

Low-dose RAD001(Everolimus) Plus Cisplatin-HDFL Chemotherapy for the First-line Treatment of Advanced Gastric Cancer

Metastatic Gastric Cancer

Taiwan
AstraZeneca

Completed

A Study of AZD8233 in Participants With Dyslipidemia. (HAYATE)

Dyslipidemia

Japan
National Cancer Center, Korea

Terminated

Phase Ib/II Trials of RAD001 in Triple Negative Metastatic Breast Cancer

Metastatic Breast Cancer

Korea, Republic of
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Carboplatin, Paclitaxel, and Everolimus in Treating Patients With Previously Untreated Cancer of Unknown Primary

Carcinoma of Unknown Primary Origin

United States
Lepu Medical Technology (Beijing) Co., Ltd.

Unknown

NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial

Coronary Artery Disease

China
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Erlotinib and Everolimus in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Heinrich-Heine University, Duesseldorf

Terminated

Trial to Evaluate Paclitaxel Plus RAD001 in Urothelial Carcinoma (RAD001)

Bladder Cancer

Germany
GERCOR - Multidisciplinary Oncology Cooperative...

Completed

Everolimus, Carboplatin, and Paclitaxel in Locally Advanced Head and Neck Cancer That Cannot Be Removed by Surgery (CAPRA)

Head and Neck Cancer

France
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin and Everolimus in Treating Patients With Advanced Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific

United States
Herbert Hurwitz, MD
Novartis; Genentech, Inc.; Amgen

Completed

BEP Study Phase I (Bevacizumab, Everolimus, Panitumumab) (BEP)

Solid Tumors

United States
Novartis Pharmaceuticals

Completed

3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial (LUNA)

Neuroendocrine Carcinoma of the Lung and Thymus

Italy, United Kingdom, Netherlands, Spain, Germany, France, Greece, Denmark, Sweden
Takeda

Terminated

Efficacy and Safety of TAK-379 in Adult Subjects With Type 2 Diabetes Mellitus

Diabetes Mellitus

United States
Novartis Pharmaceuticals

Completed

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Liver Transplant Recipient

Belgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients (RAD)

Liver Transplantation

United States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment

Unspecified Adult Solid Tumor, Protocol Specific

United States
International Extranodal Lymphoma Study Group (IELSG)

Completed

Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)

Marginal Zone B-cell Lymphoma

Italy, Switzerland, Austria
Richard Stone, MD
Massachusetts General Hospital; Novartis; Beth Israel Deaconess Medical Center; Brigham and Women's Hospital

Active, not recruiting

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Memorial Sloan Kettering Cancer Center
Johns Hopkins University; Novartis Pharmaceuticals; University of California,... and other collaborators

Completed

Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) With Leuprolide + Letrozole and (3) Everolimus + EDT in Patients With Unresectable Fibrolamellar Hepatocellular Carcinoma (FLL-HCC)

Fibrolamellar Carcinoma | Fibrolamellar Liver Cancer

United States
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.

Renal Transplantation

France
Abbott Medical Devices

Completed

XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)

Myocardial Ischemia | Coronary Artery Disease | Angina Pectoris | Ischemic Heart Disease | Coronary Artery Occlusion

Japan
AIO-Studien-gGmbH
Novartis Pharmaceuticals; iOMEDICO AG

Completed

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (VicTORia)

Her2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast Cancer

Germany
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Lymphoma | Multiple Myeloma and Plasma Cell Neoplasm

United States
Fox Chase Cancer Center
Novartis Pharmaceuticals

Terminated

Sporadic Angiomyolipomas (AMLs) Growth Kinetics While on Everolimus (SAGE)

Sporadic Angiomyolipomas (AMLs)

United States
Yale University
Novartis Pharmaceuticals

Terminated

Neoadj ph 2 AI Plus Everolimus in Postmenopausal Women w/ ER Pos/HER2 Neg, Low Risk Score

Breast Cancer

United States
Novartis Pharmaceuticals

Completed

A Prospective, Open Label Study of CERtican in KIdney Transplantation (CERKI)

Kidney Transplant

Korea, Republic of
Gustave Roussy, Cancer Campus, Grand Paris

Terminated

Assessing Everolimus in Fist Line Treatment on Patients With Metastatic Kidney Cancer (POORTOR)

Kidney Cancer

France
Herlev Hospital
Odense University Hospital; Aalborg University Hospital

Completed

Irinotecan, Cetuximab and Everolimus to Patients With Metastatic Colorectal Cancer (ICE)

Metastatic Colorectal Cancer

Denmark
Novartis Pharmaceuticals

Completed

Safety, Tolerability and Efficacy of Everolimus With Lower Versus Higher Levels of Tacrolimus in de Novo Renal Transplant Patients

Renal Transplantation
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer

Breast Cancer

China
Seoul National University Hospital

Unknown

Comparison of the Efficacy of Paclitaxel-releasing Balloon Catheter System Versus the Everolimus-Eluting Stent System for Treatment of In-Stent Restenosis Lesions - Harmonizing Optimal Strategy for Treatment of In-Stent Restenosis Lesions (The HOST-ISR Trial) -

In-stent Restenosis Lesion

Korea, Republic of
University of Giessen
Novartis; Hoffmann-La Roche; Astellas Pharma Inc; Heidelberg University

Completed

Impact of Immunosuppressive Regimens on Polyomavirus-related Transplant Nephropathy

Polyomavirus Infections

Germany
National Taiwan University Hospital
Novartis

Unknown

ESR1 Mutations in Asian ER+ Metastatic Breast Cancer on Hormonal Therapy-based Treatments

Metastatic Breast Cancer

Taiwan
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

Breast Cancer

United States
Duke University
Novartis; Pfizer

Completed

Phase II Study of Afinitor vs. Sutent in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN)

Advanced Non-clear Cell Renal Cell Carcinoma

United States, Canada, United Kingdom
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Completed

Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer

Breast Cancer

United States
Raul Moreno

Completed

Non-acute Coronary occlusIon Treated By Everolimus ELuting Stent (CIBELES)

Coronary Artery Disease | Percutaneous Coronary Intervention | Coronary Occlusion
Novartis Pharmaceuticals

Completed

RAMSETE: RAD001 in Advanced and Metastatic Silent Neuro-endocrine Tumors in Europe (RAMSETE/CDE16)

Carcinoma | Neuroendocrine | Advanced and Metastatic Silent Neuro-Endocrine Tumors | Non Functioning Neuroendocrine Tumors (NETs) | Non Syndromic Neuroendocrine Tumors | Carcinoids | Non Functioning

Sweden, Italy, Germany, United Kingdom, Spain, France, Netherlands, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Everolimus (RAD001) in Patients With Advanced Gastric Cancer

Advanced Gastric Cancer

Japan

Search clinical trials for: AZD9833 with everolimus

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Mali

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations